Genfit: 41% sales growth in 2023
It points out that 13.3 million in revenues are attributable to a milestone payment invoiced to Ipsen in December 2023, following acceptance of the NDA filing with the FDA and the filing of the MA application with the EMA for accelerated approval of elafibranor.
At December 31, 2023, Genfit's cash and cash equivalents amounted to 77.8 million euros (versus 140.2 million a year earlier), an amount not including the milestone payment from Ipsen, received in February 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction